AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 7%
#293 out of 4595 analysts
Average Return
+28.18%
Win Rate
53%30 out of 57
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-22 - 2021-03-09 | Strong Buy |
Nuvalent IncNUVL | +222.66% | $13.59 | $43.85 | 2022-06-24 - 2023-06-23 | Buy |
C4 Therapeutics IncCCCC | +220.51% | $1.56 | $5.00 | 2023-11-03 - 2024-05-31 | Buy |
Immunogen IncIMGN | +201.35% | $5.19 | $15.64 | 2022-11-16 - 2023-11-15 | Buy |
Y Mabs Therapeutics IncYMAB | +172.75% | $4.44 | $12.11 | 2023-01-30 - 2024-01-29 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Acrivon Therapeutics IncACRV | 5 | Buy | $25.00 | +223.83% | Reiterates | 19 days ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | +63.04% | Maintains | 24 days ago |
Macrogenics IncMGNX | 7 | Hold | $8.00 | +95.60% | Downgrades | 24 days ago |
Cytomx Therapeutics IncCTMX | 8 | Hold | $3.59 | +111.18% | Maintains | 25 days ago |
Biontech SeBNTX | 3 | Buy | $122.00 | +21.27% | Maintains | a month ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | +5.10% | Maintains | a month ago |
Novartis AgNVS | 2 | Hold | $116.00 | +12.48% | Maintains | a month ago |
Terns Pharmaceuticals IncTERN | 2 | Buy | $19.00 | +216.14% | Maintains | 3 months ago |
Y Mabs Therapeutics IncYMAB | 4 | Buy | $26.00 | +114.88% | Maintains | 3 months ago |
Merus NvMRUS | 4 | Buy | $58.00 | +8.94% | Maintains | 3 months ago |
Xencor IncXNCR | 2 | Buy | $34.00 | +43.10% | Maintains | 3 months ago |
Nuvalent IncNUVL | 4 | Buy | $102.00 | +55.44% | Maintains | 3 months ago |
Arvinas IncARVN | 1 | Buy | $90.00 | +171.58% | Maintains | 3 months ago |
Genmab AGMAB | 2 | Buy | $48.00 | +70.21% | Upgrades | 3 months ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | -0.74% | Downgrades | 6 months ago |
C4 Therapeutics IncCCCC | 2 | Buy | $16.00 | +220.00% | Maintains | 7 months ago |
Inventiva SaIVA | 2 | Strong Buy | $12.00 | +226.98% | Reiterates | 9 months ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | a year ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | a year ago |
Exelixis IncEXEL | 1 | Buy | $28.00 | N/A | Initiates Coverage On | 2 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 2 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 3 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 3 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 4 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.